Phosphagenics Limited has identified what appear to be irregular transactions in relation to its invoicing and accounting records. Pending finalization of the investigation, the company's Board of Directors has suspended Dr. Esra Ogru from performing her functions as CEO. In the interim, Executive Director and joint CEO Harry Rosen has returned from the company's New York office to assume the role of sole CEO.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.003 AUD | 0.00% | -25.00% | -14.29% |
03:43am | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
1st Jan change | Capi. | |
---|---|---|
-14.29% | 6.35M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.13% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- AVE Stock
- News Avecho Biotechnology Limited
- Phosphagenics Limited Suspends Esra Ogru as Chief Executive